Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YK012 in Primary Membranous Nephropathy
NCT07234474Phase 1Not yet recruiting
- Sponsor
- Excyte Biopharma Ltd
- Start
- Sep 2027
- Primary completion
- Oct 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
01
Overview
Phase 1, open-label trial of YK012 in primary membranous nephropathy (PMN) (2 arms), sponsored by Excyte Biopharma Ltd. Primary endpoints: Dose-Limiting Toxicity at 28 days, Adverse Event at 53 weeks and 1 more. Planned start Sep 2027; status: not yet recruiting.
02
Drugs
YK012
03
Conditions
primary membranous nephropathy (PMN)
Beyond the preview
Go deeper on NCT07234474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07234474.